Year: 2024

Two 340B Terminations, Two Paybacks to Manufacturers in Latest Provider Audit Findings

January 5, 2024 Rich Daly, Editor in Chief Views

Federal auditors determined terminations from the 340B program were required for either covered entity sites or a contract pharmacy of two more 340B providers.

Federal auditors determined terminations from the 340B program were required for either covered entity sites or a contract pharmacy of [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

2024 Congressional 340B Outlook: Overhaul Unlikely Without Major Legal Developments, Senate Deal

January 5, 2024 William Newton, Associate Editor/Senior Writer Views

A Senate Committee recently approved the FY25 Departments of Labor, Health and Human Services, Education and Related Agencies Appropriations Act.

In 2024, congressional gridlock and election year dynamics will likely slow momentum on any comprehensive 340B program reform package, lobbyists [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Expert Tip from RxStrategies – Jan 24

January 5, 2024 Sponsored Content Views

Novo Nordisk, Arkansas Reach Temporary Deal Amid Contract Pharmacy Fight

January 4, 2024 Rich Daly, Editor in Chief Views

Arkansas Insurance Department office sign

The Arkansas Insurance Department will imminently enforce a state 340B contract pharmacy law following a key federal appeals court decision.

Novo Nordisk will lift restrictions in Arkansas on 340B providers’ contract pharmacy arrangements and Arkansas will suspend enforcement against the [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Gilead Expands 340B Reporting to Wholly Owned Contract Pharmacies

January 3, 2024 Rich Daly, Editor in Chief Views

Gilead Sciences will expand its data reporting requirements for 340B pricing on branded hepatitis C products to contract pharmacies wholly owned by covered entities.

Drugmaker Gilead Sciences will expand its data reporting requirements for 340B pricing on branded hepatitis C products to contract pharmacies [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Hospital Groups Urge Federal Court to Dismiss Drug Industry Suit Against Louisiana Law

January 3, 2024 Ted Slafsky, Publisher & CEO Views

Four hospital associations filed an amicus brief in support of Louisiana Attorney General Jeff Landry's defense of his state's contract pharmacy law.

Four hospital associations are asking a federal judge in Louisiana to throw out a suit filed by the drug industry [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

J&J Offers Refunds on Blockbuster Drug, Other Manufacturers Update NDCs

January 3, 2024 Rich Daly, Editor in Chief Views

Johnson & Johnson has ended its contract pharmacy restrictions for Arkansas covered entities.

Drugmaker Johnson & Johnson will offer refunds to 340B providers related to the purchases of four of its drugs, including [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

2023 Contract Pharmacy Developments: Surging Restrictions, State Law Legal Battles

January 3, 2024 William Newton, Associate Editor/Senior Writer Views

In 2023, Arkansas became the first state to move to enforce a 340B contract pharmacy law as manufacturer restrictions continued to increase.

In 2023, the battle over the use of contract pharmacy arrangements by 340B providers was marked by increasing drugmaker restrictions, [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Year: 2024

Two 340B Terminations, Two Paybacks to Manufacturers in Latest Provider Audit Findings

Please Login or Become a Paid Subscriber to View this Content

If you are already a

2024 Congressional 340B Outlook: Overhaul Unlikely Without Major Legal Developments, Senate Deal

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Top 10 Most Read 340B Report Articles in 2023

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Expert Tip from RxStrategies – Jan 24

News Alert

Novo Nordisk, Arkansas Reach Temporary Deal Amid Contract Pharmacy Fight

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Gilead Expands 340B Reporting to Wholly Owned Contract Pharmacies

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Hospital Groups Urge Federal Court to Dismiss Drug Industry Suit Against Louisiana Law

Please Login or Become a Paid Subscriber to View this Content

If you are already a

J&J Offers Refunds on Blockbuster Drug, Other Manufacturers Update NDCs

Please Login or Become a Paid Subscriber to View this Content

If you are already a

2023 Contract Pharmacy Developments: Surging Restrictions, State Law Legal Battles

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

News Alert

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Site Footer Live